

30<sup>th</sup> May, 2018

✓ The Dy. General Manager (Listing Dept.)  
BSE Limited.,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

~~The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)~~

Dear Sir,



**Sub.: Presentation to analysts on audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018**

The presentation on audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



 MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

**Encl.:** As above



**Q4 & FY 2017-18**



## Consolidated Revenues for Q4 2017-18

( ₹ Crore)

Particulars	Q4 1718	Q4 1617	Gr%
India	693	467	48%
US	307	280	9%
Brazil	215	216	-1%
Germany	248	235	6%
Other	132	117	13%
Others (Incl contract Mfg.)	127	119	7%
<b>Total</b>	<b>1,722</b>	<b>1,434</b>	<b>20%</b>



## Consolidated Revenues for FY 2017-18

(` Crore)

Particulars	YTD 1718	YTD 1617	Gr%
India	2,351	1,976	19%
US	1,100	1,346	-18%
Brazil	709	700	1%
Germany	912	811	12%
Other	522	479	9%
Others (Incl contract Mfg.)	408	545	-25%
<b>Total</b>	<b>6,002</b>	<b>5,857</b>	<b>2%</b>

